Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2009 Jul;135(7):961-7.
doi: 10.1007/s00432-008-0532-x. Epub 2008 Dec 24.

Toxicity of daily low dose cisplatin in radiochemotherapy for locally advanced head and neck cancer

Hendrik Andreas Wolff  1 , Tobias Overbeck, Ralph M Roedel, Robert M Hermann, Markus K A Herrmann, Tereza Kertesz, Hilke Vorwerk, Andrea Hille, Christoph Matthias, Clemens F Hess, Hans Christiansen
Affiliations
Clinical Trial

Toxicity of daily low dose cisplatin in radiochemotherapy for locally advanced head and neck cancer

Hendrik Andreas Wolff et al. J Cancer Res Clin Oncol. 2009 Jul.

Abstract

Purpose: To evaluate toxicity of radiochemotherapy schedule using daily-low-dose-cisplatin in radiochemotherapy of locally-advanced head-and-neck-cancer (HNSCC).

Methods and patients: From October 2003 to October 2006, 50 patients with HNSCC (stage III/IVA/IVB) were treated. In 32 patients, surgery and adjuvant radiotherapy(64 Gy), in 18 patients definitive radiotherapy(70 Gy) was performed. Low-dose-cisplatin was applied concomitantly (6 mg/m2/every radiotherapy-day).

Results: Acute toxicity > or =grade 3 was observed in 22 patients (11 patients mucositis/dysphagia, 7 hematologic toxicity, 4 mucositis/dysphagia/hematologic toxicity). 90% of our patients received >80% of the planned cumulative chemotherapy dose, 94% the intended dose of radiotherapy. After median follow-up of 24.2 months, 3-year overall survival and loco-regional control rates were 67.1 and 78%. During follow-up, chronic toxicity > or =grade 3 (xerostomia, subcutaneous fibrosis, or lymphedema) was observed in nine patients.

Conclusion: We found chemoradiation with daily-low-dose-cisplatin to be feasible with advantage of low acute and chronic toxicity. Therefore, use of low-dose-cisplatin should be evaluated in future clinical trials.

PubMed Disclaimer

References

    1. Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF et al (2003) An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21:92–98. doi:10.1200/JCO.2003.01.008 - PubMed
    1. Adelstein DJ, Saxton JP, Rybicki LA, Esclamado RM, Wood BG, Strome M, Lavertu P et al (2006) Ma Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution. J Clin Oncol 24:1064–1071. doi:10.1200/JCO.2005.01.5867 - PubMed
    1. Bauchaud JM, Cohen-Jonathan E, Alzieu C, David JM, Serrano E, Daly-Schveitzer N et al (1996) Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. Int J Radiat Oncol Biol Phys 36(5):999–1004. doi:10.1016/S0360-3016(96)00430-0 - PubMed
    1. Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH et al (2004) Postoperative Irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350:1945–1952. doi:10.1056/NEJMoa032641 - PubMed
    1. Browman GP, Hodson DI, Mackenzie RJ, Bestic N, Zuraw L (2001) Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: a systematic review of the published literature with subgroup analysis. Head Neck 23:579–589. doi:10.1002/hed.1081 - PubMed

Publication types

MeSH terms